Psychiatry

Treatment with benzodiazepines, antipsychotics, and antidepressants was associated with an increased risk of all-cause hospitalization or mortality, while mood stabilizer treatment did not have a statistically significant association with any of the predetermined outcomes and ADHD medications were linked to a lower risk of psychiatric hospitalization.

New research highlights the shared and unique characteristics of sleep and rest-activity rhythm measures among patients with schizophrenia.

There was an increase in depression in the cystic fibrosis group, as well as an increase in anxiety in cystic fibrosis caregivers during the pandemic.

For older adults, 19.4% of exposures resulted in death or other major outcomes and there were twice as many cases that involved children aged 5-13 years in 2021 compared to 2019.

Scores for the 20-Item Symptom Checklist improved from baseline over gestation in the interpersonal psychotherapy cohort, but not in the enhanced usual care group.

The results show depressive disorders in the first cohort were associated with a nearly 4-fold higher risk of depressive disorders in the spousal cohort.

A cross-sectional analysis of data is offering a snapshot of trends in the treatment of 7 common chronic health conditions among incarcerated populations in the US relative to the general population.

Evidence shows digital cognitive behavioral therapy for insomnia is more effective than medication therapy, with comparable effectiveness to combination therapy.

State adoption of both SNAP eligibility policies, where the state eliminates the asset test and increases the income limit resulted in decreases in the rates of past-year major depressive episodes, mental illness, serious mental illness, and suicidal ideation.

Electroconvulsive therapy was superior to ketamine in a sensitivity analysis of methodologically stronger trials and also was better in study-defined response and remission for patients with major depressive episodes.

A new study has found individuals with depression and insomnia show significantly less activity in the prefrontal cortex during verbal fluency tests, suggesting that sleep quality is an important indicator in fNIRS screening.

The risk of minor nuisances, violating APS law, and violating criminal law were higher in the nonadherence group.

The proportion of AUD treatment engagement did not differ between the 2 time periods, but intervention increased intermediate outcomes, including screening, new AUD diagnosis, and treatment initiation.

Investigators found girls with depression and anxiety responded especially well to melatonin treatment, suggesting the potential of sleep interventions in reducing the risk of self-harm.

There was also significantly greater reductions in anxiety, Afghan-cultural distress symptoms, and psychiatric difficulties compared to the treatment as usual group.

The probability of using a firearm when alcohol is consumed was higher in the male decedents compared to female decedents.

Future research could explore the factors contributing to this disparity and identify effective interventions to reduce tobacco use in this population.

Patients in the top half of the cohort for both clinical severity and instability were at an increased risk of hospitalization than those at the bottom half of both dimensions

Various psychiatric symptoms, including more severe negative symptoms, lower cognition status, and lower excited symptoms were significantly linked to drug-induced parkinsonism induction.

TCAs caused more examples of severe dry mouth, both objectively and subjectively, while SSRIs were associated with less severe symptoms.

There was very little evidence of an effect growth or increased risk of psychiatric or neurological adverse events in the methylphenidate group compared with the no-methylphenidate group.

Prism for PTSD uses self-neuromodulation techniques to lower the amygdala-derived-EPP biomarker, which is linked to the amygdala and emotion regulation system.

There was a lower probability of initiating psycholeptics and having postpartum psychiatric emergencies in the early discontinuer and late discontinuer groups compared to the continuers.

Zuranolone is being evaluated as a 14 day, rapid-acting, once-daily, oral treatment for adult patients with MDD and PPD. The drug is an oral neuroactive steroid GABA-A receptor positive allosteric modulator.

The results show 28.9% of the aripiprazole augmentation group achieved remission, compared to 28.2% of the bupropion augmentation group and 19.3% of the bupropion switch group.